Stem Cell Research and News: Canada
<-- Back To RegionsEgg Like Cells Produced From Pig Fetal Stem Cells
Canadian stem cell researchers at the University of Guelph are reporting that they have discoverd stem cells within the skins of pig fetuses are able to produce egg-like cells. Embryologists have been investigating for years to determine where germ cells...
Posted in Today's Stem Cell Research on March 29, 2006 03:56 PM
Stem Cell Researchers Again Improving Spinal Cord Injured Rats
Stem cell researchers are once again looking into the brains of mice and how some stem cell therapies can help restore walking ability in laboratory rats with spinal-cord damage. Canadian stem cell researchers are now digging into spinal stem cell...
Posted in Today's Stem Cell Research on March 29, 2006 11:10 AM
Multiple Sclerosis Sufferer Sees Results From Stem Cell Therapy
A new stem cell procedure designed to treat Multiple Sclerosis has been tested in Canada with some significant results for at least one person so far. Doctors harvested stem cells from Jennifer Molson of Ottawa. Following that, Molson was given...
Posted in Today's Stem Cell Research on March 17, 2006 01:13 PM
Lupus Stem Cell Treatment Study in Chicago Shows Promise
News is coming out of Chicago about rebuilding the immune system of patients suffering from Lupus with their own stem cells can promote remission in some of the most severely ill, when other forms of treatment have failed .. this...
Posted in Today's Stem Cell Research on February 2, 2006 12:32 AM
Stem Cell Therapeutics Corp. to Present at BioContact Québec
CALGARY, Oct. 5 /CNW/ - Dr. Joseph Tucker, President and CEO of Stem Cell Therapeutics Corp. ("SCT"), will present a corporate update focusing on the clinical trial development of SCT's lead program, NTx(TM)-265, at BioContact Québec 2005. More than 150...
Posted in Today's Stem Cell Research on October 4, 2005 05:45 PM
Restorative Therapies, Inc., Receives FDA Clearance for RT300-S
BALTIMORE, MD -- (Market Wire - Aug 23, 2005) -- Restorative Therapies, Inc., a designer and supplier of medical devices, today announces FDA clearance of its breakthrough medical device, the RT300-S, a functional electrical stimulation (FES) motorized cycle ergometer. In...
Posted in Today's Stem Cell Research on August 24, 2005 12:10 AM
More on Skin Cells "Made Into" Embryonic Stem Cells
Following up on the embryonic stem cells created from skin cells ... this news is flying wildly all over the internet ... with posts coming in from many sources .. will try to post a few of them here ......
Posted in Today's Stem Cell Research on August 23, 2005 09:03 AM
ThermoGenesis Corp. Initiates Shipments of Thrombin Processing Devices(TM) (TPD(TM)) To Biomet, Inc.
Agreement Allows Biomet to Immediately Market Their Gravitational Platelet Separation System (GPS) in Europe, Canada and Asia as a Fully Autologous Product RANCHO CORDOVA, Calif., Aug. 16 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL - News) announced today that the Company...
Posted in Today's Stem Cell Research on August 16, 2005 05:32 PM
London, Ontario Stem Cell Researcher Heads to McMaster
Robarts Research Institute, in Canada is losing yet another top stem cell scientist. 35-year Dr. Mick Bhatia has already been offered more than $500,000 U.S. to move to the US. Dr. Bhatia has thusfar turned down American offers and instead...
Posted in Today's Stem Cell Research on August 11, 2005 05:19 PM
ViaCell, Inc. Reports Second Quarter 2005 Financial Results
CAMBRIDGE, August 9, 2005 - ViaCell, Inc. (Nasdaq: VIAC), a clinical-stage biotechnology company dedicated to enabling the widespread application of human cells as medicine in the areas of cancer, cardiac disease, diabetes and infertility, today reported financial results for the...
Posted in Today's Stem Cell Research on August 10, 2005 05:22 PM
ViaCell, Inc. to Announce Second Quarter Results on August 9, 2005
CAMBRIDGE, Mass., Aug. 2 /PRNewswire-FirstCall/ -- ViaCell, Inc. (Nasdaq: VIAC - News) announced today that it will report second quarter 2005 results on Tuesday August 9, 2005 at 8:30 a.m. Eastern Time. Following the announcement, ViaCell senior management will host...
Posted in Today's Stem Cell Research on August 9, 2005 05:15 PM
Curis to Release 2005 Second Quarter Financial Results and Hold Conference Call on August 9, 2005
CAMBRIDGE, Mass., Aug. 2, 2005 - Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company, will release its second quarter financial results on Tuesday, August 9, 2005 before the market opens. The Company will also hold a conference call to...
Posted in Today's Stem Cell Research on August 8, 2005 06:13 PM
Bio-Matrix Scientific Exhibiting Stem Cell Instruments & Stem Cell Bank at the American Society of Plastic Surgeons Convention in Chicago September 24 - 28
SAN DIEGO, Aug. 3, 2005 - Bio-Matrix Scientific Group Inc. (Pink Sheets:BMXP) announced today that it will participate in the American Society of Plastic Surgeons Convention in Chicago September 24 - 28 as an exhibitor. The Company will be displaying...
Posted in Today's Stem Cell Research on August 5, 2005 02:49 PM
AnorMED Reports Fiscal 2006 First Quarter Results, Progress on Phase III Trials, and Announces New Vice President, Marketing
Vancouver, British Columbia - AnorMED Inc. (TSX:AOM) today reported financial results for its first fiscal quarter ended June 30, 2005. AnorMED recorded a net loss of $8,025,000 ($0.25 per common share) in this quarter. This is in comparison to the...
Posted in Today's Stem Cell Research on August 5, 2005 02:33 PM
The Leukemia & Lymphoma Society Honors Five Scientists for Outstanding Work in Blood Cancer Research
Stem cell researchers are now seen as major contributors in the development of potental treatments for leukemia and lymphoma by the Leukemia & Lymphoma Society. As a result, they are being honored with the Stohlman Scholar Award. ..... WHITE PLAINS,...
Posted in Today's Stem Cell Research on August 3, 2005 04:13 PM
StemCyte, Inc. Completes Significant Round of Financing
Leader in Stem Cell Technology Adds New Investors ARCADIA, Calif., July 19 /PRNewswire/ - StemCyte®, Inc., a leading umbilical cord blood stem cell transplantation and therapeutic products company, today announced it has recently completed a significant round of financing from...
Posted in Today's Stem Cell Research on July 26, 2005 01:55 PM
The Leukemia & Lymphoma Society Publishes New Coloring Book to Help Children Receiving Stem Cell Transplants
WHITE PLAINS, NY - For a child with blood cancer, getting a stem cell transplant often involves long stays at the hospital, with much of the time spent in isolation. The Leukemia & Lymphoma Society has produced a new coloring...
Posted in Today's Stem Cell Research on July 26, 2005 01:00 AM
Canada's Bioms Medical Commences U.K. Patient Enrollment in Multiple Sclerosis Trial
Edmonton, Alberta, July 21, 2005 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the first patients in the United Kingdom have been enrolled in its pivotal Phase II/III clinical...
Posted in Today's Stem Cell Research on July 22, 2005 05:15 PM
Lifebank Grants Stock Options
BURNABY, BRITISH COLUMBIA--(CCNMatthews - July 11, 2005) - Lifebank Cryogenics Corp. (TSX VENTURE:LBK) announces that, under it's stock option plan, it has granted incentive stock options to directors, officers and employees of the Company to purchase up to a total...
Posted in Today's Stem Cell Research on July 12, 2005 11:54 AM
Thermogenesis Corp. Completes Enrollment Of 150-Patient Human Clinical Trial Of CRYOSEAL® Fibrin Sealant System
RANCHO CORDOVA, California (June 22, 2005) – ThermoGenesis Corp. (NASDAQ: KOOL) announced today that enrollment is now complete for its pivotal U.S. 150-patient blinded, randomized, multi-center clinical trial for the CryoSeal Fibrin Sealant (FS) System. This pivotal trial evaluated the...
Posted in Today's Stem Cell Research on July 12, 2005 11:33 AM
Lifebank Appoints Preeminent Hematologist to Advisory Board
Lifebank Cryogenics Corp. (TSX VENTURE:LBK) is pleased to announce that Dr. Pierre Laneuville, BSc, M.D., FRCP(C), has agreed to join its medical and scientific advisory board. Dr. Laneuville is a senior physician in the division of hematology, department of medicine...
Posted in Today's Stem Cell Research on June 22, 2005 06:29 PM
Aastrom Biosciences Appoints New Chief Financial Officer
Ann Arbor, Michigan, June 20, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today the appointment of Gerald ("Jerry") D. Brennan, Jr., JD, as Vice President Administrative and Financial Operations and Chief Financial Officer. Mr. Brennan will assume his position...
Posted in Today's Stem Cell Research on June 22, 2005 01:30 AM
Victoria Launches New Human Embryonic Stem Cell Line & Drives International Stem Cell Network
MELBOURNE, Australia and PHILADELPHIA, June 19 -- A second human embryonic stem cell line to be made available to researchers worldwide without commercial or intellectual property restraints was announced by the Victorian Premier, Steve Bracks, at the global biotechnology conference...
Posted in Today's Stem Cell Research on June 19, 2005 11:34 AM
Chemokine Therapeutics Announces Dual Trading on the TSX in Canada and the OTCBB in the U.S.
Vancouver, BC (June 15, 2005) – Chemokine Therapeutics Corp. (TSX: CTI, OTCBB: CHKT), a biotechnology company developing peptide-based therapies to treat cancer, blood disorders, cardiovascular, and infectious diseases, today announced that it has established trading in the United States in...
Posted in Today's Stem Cell Research on June 16, 2005 12:55 PM
Stem Cell Research In Canada Gains Approval
The first two batches of human embryonic stem cells in Canada have been approved by an international regulator. This opens the way for researchers to evaluate potential treatments and cures targetting a variety of diseases. A team of Toronto scientists...
Posted in Today's Stem Cell Research on June 9, 2005 12:30 PM
Anormed Announces Fiscal 2005 Results and 2006 Key Events
VANCOUVER, British Columbia - AnorMED Inc. (TSX:AOM) reported today a net loss of $2,169,000 ($0.07 per common share) for the fiscal year ended March 31, 2005, compared to a net loss of $17,531,000 ($0.64 per common share) in Fiscal 2004....
Posted in Today's Stem Cell Research on June 1, 2005 06:08 PM
Researchers Look at Stem Cells to Repair Damage Caused by Multiple Sclerosis
CALGARY, May 26 /CNW/ - Three North American research centres are examining the body's own stem cells in hopes that they may hold the key to repairing damage caused by multiple sclerosis. If successful, people with MS may be able...
Posted in Today's Stem Cell Research on May 27, 2005 12:14 PM
Lifebank Cryogenics Signs Exclusive Technology License Agreement with University of Alberta in Pursuit of New Health Treatments
Burnaby, BC., May 18, 2005 - Lifebank Cryogenics Corp., the only umbilical cord blood stem cell bank in Canada to be accredited by the American Association of Blood Banks, today announced it has signed an exclusive license agreement with the...
Posted in Today's Stem Cell Research on May 24, 2005 11:05 AM
BioMS Medical announces first quarter 2005 results
EDMONTON, May 13 /CNW/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results for the first quarter ended March 31, 2005. "During the quarter, we initiated patient dosing for our...
Posted in Today's Stem Cell Research on May 13, 2005 03:15 PM
ViaCell, Inc. Reports First Quarter 2005 Financial Results
BOSTON, May 10 /PRNewswire-FirstCall/ -- ViaCell, Inc. (Nasdaq: VIAC), a clinical-stage biotechnology company dedicated to enabling the widespread application of human cells as medicine in the areas of cancer, cardiac disease, diabetes and infertility, today reported financial results for the...
Posted in Today's Stem Cell Research on May 11, 2005 03:50 PM
Geron Announces Publication of Studies Demonstrating Hematopoietic Stem Cells Differentiated From Human Embryonic Stem Cells Engraft and Establish Hematopoiesis in Animals
MENLO PARK, Calif.--(BUSINESS WIRE)--May 10, 2005--Geron Corporation (Nasdaq:GERN) announced today the publication of studies demonstrating that hematopoietic stem cells (HSCs) derived from human embryonic stem cells (hESCs) can establish hematopoiesis in mouse models, leading to production of all major human...
Posted in Today's Stem Cell Research on May 10, 2005 02:48 PM
ViaCell, Inc. to Announce First Quarter 2005 Results on May 10, 2005
BOSTON, May 05, 2005 /PRNewswire-FirstCall/ -- ViaCell, Inc. , announced today that it will report first quarter 2005 results on Tuesday, May 10, 2005 after the market close. Following the announcement, ViaCell senior management will host a conference call on...
Posted in Today's Stem Cell Research on May 5, 2005 06:31 PM
The Young & the Vigorous: Study Explains Aging Stem Cell Behavior
Newswise — A comprehensive study from Canada’s Robarts Research Institute has pinpointed two genes that shed significant light on why stem cells divide and develop less vigorously as we age. This research is the first to provide an explanation of...
Posted in Today's Stem Cell Research on May 3, 2005 05:02 PM
Stem Cell Research, Policy Implications Showcased at BIO 2005
WASHINGTON, D.C. (April 27, 2005) -- A series of thought-provoking, educational panel sessions on varying aspects of stem cell research will be showcased at the BIO 2005 Annual International Convention, June 19-22, 2005, at the Pennsylvania Convention Center in Philadelphia....
Posted in Today's Stem Cell Research on May 3, 2005 03:37 PM
BrainStorm Cell Therapeutics, Appoints Renowned Neurologists Prof. Warren Olanow and Prof. Andre Lozano to Scientific Advisory Board
NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--April 27, 2005--BrainStorm Cell Therapeutics (OTCBB:BCLI), an emerging company in stem cell therapeutics for neurological diseases, today announced that Prof. Andre Lozano and Prof. C. Warren Olanow, internationally renowned clinical neurologists and researchers, have...
Posted in Today's Stem Cell Research on May 3, 2005 12:36 PM
Curis Announces Reports of New Cancers Linked to Abnormal Hedgehog Pathway Signaling
CAMBRIDGE, Mass., April 21, 2005 - Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company, today announced that there were a number of new reports presented at the current annual meeting of the American Association for Cancer Research that corroborate...
Posted in Today's Stem Cell Research on April 22, 2005 06:01 PM
John G. Coles, MD Joins Multicell's Scientific Advisory Board Stem Cell Panel
SAN DIEGO--(BUSINESS WIRE)--April 20, 2005--MultiCell Technologies, Inc. (OTCBB: MUCL), a leading supplier of immortalized non-tumorigenic human hepatocytes as pharmaceutical candidate optimization tools, announced today that it has appointed Dr. John Coles to MultiCell's new stem cell panel of the Scientific...
Posted in Today's Stem Cell Research on April 20, 2005 08:23 PM
Serologicals' Upstate Group Sponsors Second Annual Cell Signalling Symposium June 12-15, 2005
ATLANTA, Apr 11, 2005 (BUSINESS WIRE) -- Serologicals Corporation (NASDAQ: SERO) today announced that Upstate Group, its wholly owned subsidiary, is sponsoring the Second Annual Cell Signalling Symposium to be held June 12-15, 2005, at the Apex City Quay Hotel,...
Posted in Today's Stem Cell Research on April 11, 2005 06:12 PM
ThermoGenesis Corp. to Present at SunTrust Robinson Humphrey's Annual Conference
RANCHO CORDOVA, Calif., April 11 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a pioneer in the development of systems that enable the production and storage of therapeutic components, today announced that Chairman and Chief Executive Officer, Philip H. Coelho, will be...
Posted in Today's Stem Cell Research on April 11, 2005 03:27 PM
Cord Blood Bank, Lifebank Appoints New Medical Director
BURNABY, BRITISH COLUMBIA--(CCNMatthews - April 4, 2005) - Lifebank Cryogenics Corp. (TSX VENTURE:LBK) is pleased to announce the appointment of Dr. Anil K. Mangal as its new Medical Director. Dr. Mangal is a Fellow of the Royal College of Physicians...
Posted in Today's Stem Cell Research on April 5, 2005 12:13 PM
Stem Cell Network Appoints New Leaders
OTTAWA, April 1 /CNW/ - Dr. Michael Rudnicki has been appointed the Scientific Director of the Stem Cell Network, succeeding founding director Dr. Ron Worton, who is retiring from the post. The Stem Cell Network, one of Canada's Networks of...
Posted in Today's Stem Cell Research on April 4, 2005 11:00 AM
Chemokine Therapeutics Corp. Sheet
Chemokine Therapeutics (TSX: CTI, OTCBB: CHKT) Corp. Sheet Chemokine Therapeutics Corp. Articles More Chemokine Therapeutics Corp. Articles Corporate Summary (site quote): Chemokine Therapeutics is a publicly-held biotechnology company with emphasis on peptide therapeutics. The Company discovers, develops, and manufactures innovative...
Posted in Today's Stem Cell Research on April 1, 2005 06:31 PM
Anormed Files IND to Evaluate Potential of AMD3100 to Repair Damaged Heart Tissue in Cardiac Patients
VANCOUVER, April 1 /PRNewswire-FirstCall/ - AnorMED Inc. (TSX:AOM) announced today that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration for approval to begin its clinical program for AMD3100 in cardiac patients. The...
Posted in Today's Stem Cell Research on April 1, 2005 04:34 PM
Taking Stem Cell Research from Mouse to Man - University of Toronto Bioengineer Captures Prestigious Canadian Research Prize
OTTAWA, March 31 /CNW Telbec/ - Since the headline-making discovery of the first human embryonic stem cells in 1998, there's been ongoing public buzz about the potential curative powers of these primitive cells. "At the end of the day, if...
Posted in Today's Stem Cell Research on April 1, 2005 09:40 AM
Mycamine Received FDA Approval - Fujisawa Healthcare, Inc.’s Echinocandin To Fight Candida Fungal Infections From Stem Cell Transplant
Fujisawa Healthcare, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the use of micafungin sodium, the antifungal product for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation and the treatment of esophageal...
Posted in Today's Stem Cell Research on March 20, 2005 11:36 PM
First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes
LOS ANGELES --AmCyte Inc. (www.amcyte.com), a leader in encapsulated islet replacement and pancreatic adult stem cells, announced today the transplantation of the first Type 1 diabetic patient in North America to receive islets without long-term immune suppression. The transplant took...
Posted in Today's Stem Cell Research on March 10, 2005 10:32 PM
U.S. BioDefense Retains Stem Cell Consultant Hugh Keeping, Ph.D.
U.S. BioDefense, Inc. (OTCBB: UBDE) is pleased to announce today that the company has retained the consulting services of Dr. Hugh S. Keeping Ph.D., founder of MatriExtend Technologies, a consulting firm for development and marketing of cellular diagnostic assays, to...
Posted in Today's Stem Cell Research on March 9, 2005 12:42 PM
Cord Blood Company Viacell 2004 Financials
ViaCell, Inc. (Nasdaq: VIAC), a clinical-stage biotechnology company dedicated to enabling the widespread application of human cells as medicine in the areas of cancer, cardiac disease, diabetes and infertility today reported financial results for the fourth quarter and year ended...
Posted in Today's Stem Cell Research on March 3, 2005 03:14 PM
Cord Blood Bank List
With stem cell research so closely tied to Umbilical Cord Blood, we thought it a good idea to get a somewhat comprehensive list of Cord Blood Banks put together. Additionally, since we have been tracking a many stem cell research...
Posted in Today's Stem Cell Research on February 22, 2005 01:55 PM
California: UBDE at the Internationalizing Early-Stage Clinical Drug Research & Development Conference
U.S. BioDefense, Inc. (OTCBB:UBDE) announces that they will be attending the Internationalizing Early-Stage Clinical Drug Research & Development Conference, being hosted at The Stadium Club at Dodger Stadium in Los Angeles, CA on Thursday, March 3rd, 2004. "We are very...
Posted in Today's Stem Cell Research on February 21, 2005 01:32 PM
Insception Biosciences and Protana Announce Stem Cell Collaboration
Insception Biosciences Inc., operator of Canada's largest private umbilical cord blood storage bank and a leading stem cell research company today announced that they have entered into an agreement to collaborate with Protana Inc. on a project related to biomarker...
Posted in Today's Stem Cell Research on February 18, 2005 12:54 AM
Ian Wilmut (Creator of Dolly) Plans to Obtain Stem Cells for Lou Gehrig's Disease Research
Professor Ian Wilmut, who led the team behind the world's first cloned mammal at Edinburgh's Roslin Institute in 1996, plans to obtain stem cells for research into motor neuron disease. The disease is known in Canada and in the United...
Posted in Today's Stem Cell Research on February 17, 2005 04:20 PM
Canada: Connective Tissue Stem Cells To Treat Cartilage and Bone
Stem cells in the umbilical cord's connective tissue, called mesenchymal progenitor cells, are those that go on to become bone, cartilage, muscle and other connective-tissue cells. The stem cells are found in the connective tissue surrounding blood vessels in the...
Posted in Today's Stem Cell Research on February 17, 2005 01:51 PM
Canada: Stem Cell Therapeutics Corp. Announces New Chief Clinical and Regulatory Office
Stem Cell Therapeutics Corp. (TSX-V: SSS) today announced that Alan F. Moore, Ph.D., has joined the company as Chief Clinical and Regulatory Officer. Dr. Moore will be responsible for overseeing and implementing Stem Cell Therapeutics Corp.'s clinical programs focused on...
Posted in Today's Stem Cell Research on February 16, 2005 09:48 PM
Canada: Toronto Researchers Have Discovered New of Stem Cell Source in Umbilical Cords
University of Toronto researchers have discovered an ample source of stem cells in an uncharted part of the umbilical cord, providing new hope for bone marrow transplants and tissue repair. The study, published in the February issue of Stem Cells,...
Posted in Today's Stem Cell Research on February 10, 2005 11:51 AM
AnorMED Announces Fiscal 2005 Third Quarter Results and Upcoming Key Events
AnorMED Inc. (TSX:AOM) today reported financial results for its third quarter ended December 31, 2004. AnorMED recorded net income of $15,848,000 ($0.50 per common share) in this quarter. This is in comparison to the net losses incurred in the third...
Posted in Today's Stem Cell Research on February 3, 2005 02:29 PM
Stem Cell Research Progress Regarding Diabetes
Several recent studies underline stem cell research as a basis for critically-needed therapies for type 1 diabetes. Insulin-producing cells have already been created using embryonic stem cells from mice as well as in preliminary studies using embryonic cell lines from...
Posted in Today's Stem Cell Research on January 25, 2005 06:00 PM
Stem Cell Therapeutics, Corp. (SSS) Corp. Sheet
Stem Cell Therapeutics, Corp. Articles More Stem Cell Therapeutics, Corp. Articles Corporate Summary (site quote): Calgary-based Stem Cell Therapeutics Corp. (SCT) is a biotechnology company focused on the development of its technology platform and intellectual property to selectively induce...
Posted in Today's Stem Cell Research on January 21, 2005 02:21 PM
AnorMED, Inc. (AOM.TO) Corp. Sheet
AnorMED, Inc. Articles More AnorMED, Inc. Articles Corporate Summary (site quote): AnorMED was founded in 1996 and listed on the TSX as AOM in 1999. To date, the Company has raised over $130 million to support its research and...
Posted in Today's Stem Cell Research on January 21, 2005 12:31 PM